Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer.
One hundred and sixty-five patients with advanced renal cell cancer were evaluable for combination or single-agent therapy with methyl-CCNU, vinblastine, and medroxyprogesterone. A low order or response was observed, and these agents were not proven effective as treatment for metastatic renal cell cancer. Performance status and a relatively long symptom-free interval from primary tumor to metastatic disease were found to be the most prognostically significant factors for survival.
D000230:Adenocarcinoma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008525:Medroxyprogesterone / Q000008:administration & dosage*; D009362:Neoplasm Metastasis; D009607:Nitrosourea Compounds / Q000008:administration & dosage*; D011379:Prognosis; D012673:Semustine / Q000008:administration & dosage*; D014747:Vinblastine / Q000008:administration & dosage*
D009607:Nitrosourea Compounds; D012673:Semustine; D014747:Vinblastine; D008525:Medroxyprogesterone